Ipamorelin is a synthetic pentapeptide belonging to the growth hormone-releasing peptide (GHRP) class, distinguished in research settings by its highly selective action on the ghrelin receptor (GHS-R1a). Unlike earlier GHRPs studied in laboratory models, ipamorelin has attracted significant scientific interest because preclinical research suggests it stimulates growth hormone (GH) release with a notably clean receptor profile — meaning it does not appear to substantially elevate cortisol, prolactin, or ACTH in the same manner as some other secretagogues. This selectivity has made ipamorelin a frequently investigated tool compound in peptide research.
Researchers working with ipamorelin in preclinical models have explored its role in GH pulse dynamics, downstream IGF-1 signaling, body composition endpoints, and potential synergy with growth hormone-releasing hormone (GHRH) analogs. This guide examines the current state of ipamorelin research, how the peptide is characterized mechanistically, and how the ipamorelin 10MG research format is applied in laboratory settings.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. Ipamorelin is not approved for human therapeutic use and is intended solely for in vitro and preclinical research applications.
Ipamorelin - 10MG — Research-Grade Reference Material Ipamorelin - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
KLOW (GHK-CU, BPC-157, TB-500 & KPV) 80MG
$105.00$78.75 with 1st order
SLU-PP-332 - 5MG
$75.00$56.25 with 1st order
GLP-3 (R) 10MG
$110.00$82.50 with 1st order
Frequently Asked Questions
What is ipamorelin and how is it classified in peptide research?
Ipamorelin is a synthetic pentapeptide classified as a growth hormone-releasing peptide (GHRP) and a ghrelin receptor agonist. It is studied for its ability to stimulate GH secretion with high receptor selectivity, making it a useful tool compound for researchers investigating GH pulse dynamics and downstream signaling pathways.
How does ipamorelin differ from other GHRPs studied in research?
Research suggests ipamorelin exhibits greater selectivity than earlier GHRPs such as GHRP-2 and GHRP-6. Preclinical studies indicate it produces GH release with minimal concurrent elevation of cortisol, prolactin, or ACTH — a profile that makes it a cleaner experimental tool for isolating GH-specific signaling in research models.
What receptor does ipamorelin target in laboratory models?
Ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor activated by the endogenous hormone ghrelin. Research has used ipamorelin to probe GHS-R1a signaling, GH pulse amplitude, and the interaction between the ghrelin axis and the GHRH system.
Is ipamorelin studied in combination with other peptides?
Yes. Ipamorelin is frequently explored alongside GHRH analogs such as CJC-1295 (no DAC) in research stacks. Studies have investigated the synergistic effect of simultaneously activating GHS-R1a (via ipamorelin) and the GHRH receptor (via CJC-1295), which preclinical data suggests produces amplified GH pulses compared to either compound alone.
What downstream pathways are associated with ipamorelin in research?
In preclinical models, GH release stimulated by ipamorelin is associated with downstream activation of the IGF-1 axis (via hepatic IGF-1 production), JAK-STAT signaling, and effects on lipid metabolism, protein synthesis, and cellular proliferation — all areas actively investigated by researchers studying secretagogue biology.
What does the 10MG research format of ipamorelin mean?
The 10MG designation refers to the total quantity of lyophilized ipamorelin peptide in a research vial. This format is standard for preclinical peptide research, allowing researchers to prepare reconstituted solutions at precise concentrations for in vitro assays or animal model studies.
Has ipamorelin been studied in bone or body composition research?
Yes. Several preclinical studies have investigated ipamorelin’s effects on bone mineral density and lean body mass in animal models, particularly in the context of GH deficiency or age-related decline. Research in these areas is ongoing and largely confined to preclinical settings.
Where can researchers source ipamorelin for laboratory use?
Ipamorelin for research purposes is available from specialized peptide suppliers. SourcePeptides.co offers an ipamorelin 10MG nasal spray research format as well as a standard injectable-grade vial, both intended exclusively for laboratory and preclinical research applications.
Ipamorelin: Molecular Profile and Receptor Pharmacology
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide designed to mimic the GH-releasing activity of ghrelin while minimizing off-target receptor interactions. Its molecular weight is approximately 711.9 Da, and its synthetic backbone confers relative stability compared to endogenous ghrelin, making it a practical research tool compound.
Ipamorelin - 10MG — Research-Grade Reference Material Ipamorelin - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
KLOW (GHK-CU, BPC-157, TB-500 & KPV) 80MG
$105.00$78.75 with 1st order
SLU-PP-332 - 5MG
$75.00$56.25 with 1st order
GLP-3 (R) 10MG
$110.00$82.50 with 1st order
GHS-R1a Agonism and Selectivity
The central pharmacological feature that distinguishes ipamorelin in the GHRP research literature is its selectivity profile. Studies published in peer-reviewed journals have compared ipamorelin head-to-head with GHRP-2 and GHRP-6 and found that while all three stimulate GH release via GHS-R1a, ipamorelin produces significantly less adrenocorticotropic hormone (ACTH) and cortisol elevation. This is understood to result from ipamorelin’s reduced affinity for receptor subtypes and signaling cascades that govern HPA axis stimulation. For researchers studying GH biology specifically — without HPA axis confounds — this selectivity makes ipamorelin an attractive experimental design choice.
GH Pulse Amplitude and Frequency Research
Growth hormone is naturally secreted in pulsatile bursts regulated by the interplay between GHRH (stimulatory) and somatostatin (inhibitory). Research has demonstrated that ipamorelin administration in preclinical models increases GH pulse amplitude without substantially altering pulse frequency, a distinction that has implications for how researchers model physiological versus pharmacological GH secretion. This pulsatile preservation is considered an important feature in research designs aimed at studying downstream IGF-1 signaling trajectories.
Downstream Signaling Pathways Explored in Ipamorelin Research
When GHS-R1a is activated by ipamorelin in preclinical models, the downstream signaling cascade engages several key biological pathways that researchers have characterized in animal and cell-based studies.
IGF-1 Axis Activation
The most studied downstream consequence of ipamorelin-stimulated GH release is hepatic production of insulin-like growth factor 1 (IGF-1). Research models have consistently shown that GH pulses drive hepatic GH receptor activation, triggering JAK2-STAT5b phosphorylation and subsequent IGF-1 gene transcription. IGF-1, in turn, mediates many of the anabolic and cellular repair effects associated with GH axis activity, including protein synthesis signaling via PI3K/Akt/mTOR pathways. Ipamorelin research often measures serum IGF-1 levels as a surrogate readout for successful GH axis engagement.
Lipid Metabolism and Body Composition Studies
Several preclinical investigations have explored ipamorelin’s effects on body composition endpoints, particularly lean mass accretion and adipose tissue dynamics. In rodent models, sustained GH secretagogue exposure has been associated with increased nitrogen retention and changes in fat mass distribution, effects attributed primarily to the downstream IGF-1 axis rather than direct ipamorelin action on peripheral tissues. These findings have informed research into GH secretagogues as investigational tools in metabolic biology.
Bone Mineral Density Research
An area of particular interest in ipamorelin research is skeletal biology. Studies in ovariectomized rat models and aged rodents have investigated whether GHS-R1a stimulation with ipamorelin can attenuate bone loss or support bone mineral density (BMD). Research published in the early 2000s demonstrated statistically significant increases in BMD markers in treated animals compared to controls, supporting continued investigation of secretagogue biology in skeletal research contexts.
Ipamorelin + CJC-1295: The Dual-Axis Research Stack
One of the most frequently discussed research applications of ipamorelin is its combination with the GHRH analog CJC-1295 (no DAC). This dual-peptide approach targets two distinct but complementary receptors: GHS-R1a (ipamorelin) and the GHRH receptor (CJC-1295 no DAC). Preclinical research has characterized the synergy between these two mechanisms — ghrelin-axis stimulation and GHRH-axis stimulation — as producing amplified GH pulses that exceed those generated by either compound in isolation.
The mechanistic rationale is well supported by endocrinology research: GHRH increases somatotroph sensitivity and GH synthesis, while ghrelin receptor agonists release GH from primed somatotrophs and suppress somatostatin tone. When both pathways are activated simultaneously, the resulting GH pulse is substantially larger than with single-agent stimulation. For researchers modeling maximal GH axis activation in preclinical systems, the CJC-1295 + ipamorelin stack has become a standard experimental reference condition.
CJC-1295 No DAC + Ipamorelin 10MG Nasal Spray for research →
Ipamorelin 10MG Nasal Spray for research →
Ipamorelin Research Formats: 10MG Vial and Nasal Spray
Researchers working with ipamorelin have access to multiple delivery format configurations. Understanding the distinctions between these formats is relevant to experimental design.
Standard 10MG Lyophilized Vial
The ipamorelin 10MG vial format contains lyophilized peptide that researchers reconstitute with sterile bacteriostatic water prior to use. This format is standard for subcutaneous administration in animal model studies and allows precise dosing based on reconstituted concentration. The lyophilized form offers stability advantages for peptide integrity during storage and shipping. Researchers typically prepare solutions at concentrations appropriate for their specific model system and administration volume requirements.
Nasal Spray Research Format
A growing area of peptide research methodology involves intranasal delivery, which researchers have explored as an alternative route that bypasses first-pass metabolism and leverages the olfactory and trigeminal nerve pathways for CNS-adjacent delivery. The ipamorelin 10MG nasal spray format is used in research settings where intranasal administration is part of the experimental design. This format is particularly relevant for researchers studying systemic GH axis modulation via mucosal absorption, as well as those designing studies that avoid parenteral routes.
Ipamorelin 10MG Nasal Spray — research format →
CJC-1295 No DAC + Ipamorelin 10MG — injectable research format →
Research Applications Summary: What Scientists Investigate with Ipamorelin
Ipamorelin has been applied across a range of preclinical research contexts. The following represents a summary of the primary investigation areas documented in the scientific literature:
- GH pulse dynamics: Characterizing GH amplitude, duration, and frequency following GHS-R1a stimulation in rodent and primate models
- IGF-1 axis studies: Measuring hepatic IGF-1 production as a functional readout of GH secretagogue activity
- Body composition research: Investigating lean mass and adipose tissue responses in GH-deficient or aged animal models
- Skeletal biology: Exploring BMD and bone formation markers in preclinical models of bone loss
- Secretagogue selectivity studies: Comparative pharmacology research benchmarking ipamorelin against GHRP-2, GHRP-6, and hexarelin for receptor selectivity and side-effect profiles
- Synergy research: Dual-axis GH stimulation studies combining ipamorelin with GHRH analogs to characterize additive and synergistic GH release
- GI motility research: Emerging preclinical investigation of GHS-R1a agonism in enteric nervous system models, given the high GHS-R1a expression in gastrointestinal tissue
Where Ipamorelin Fits in Your Research Library
Researchers building a comprehensive GH-axis research program will find ipamorelin serves as a foundational GHRP tool compound. Its selectivity profile makes it useful as a reference standard in comparative secretagogue studies, and its well-characterized receptor pharmacology provides a clean experimental baseline. The following related research compounds are frequently studied alongside or compared to ipamorelin:
CJC-1295 with DAC 5MG Nasal Spray — GHRH analog for sustained GH pulse research →
IGF-1 LR3 1MG — downstream IGF-1 axis research compound →
MOTS-C 10MG Nasal Spray — mitochondrial peptide for metabolic research alongside GH studies →
Final Takeaway: Ipamorelin as a Selective GHRP Research Tool
Ipamorelin occupies a well-defined position in the peptide research landscape as one of the most receptor-selective GHRPs studied in preclinical models. Its ability to stimulate GH pulses through GHS-R1a agonism — with minimal disruption to the HPA axis — makes it a methodologically clean tool compound for researchers focused on GH biology, IGF-1 signaling, skeletal research, and body composition endpoints. The availability of ipamorelin in both standard 10MG vial formats and nasal spray research configurations allows flexibility in experimental design across a range of administration route studies.
Whether studied in isolation or as part of a dual-axis stack with CJC-1295, ipamorelin continues to be a central compound in the secretagogue research field. Researchers exploring GH pulse dynamics, downstream anabolic signaling, or comparative GHRP pharmacology will find ipamorelin’s established literature base and selective receptor profile make it a valuable addition to any peptide research program.
Sources & Further Reading
- Raun K et al. — “Ipamorelin, the first selective growth hormone secretagogue” — European Journal of Endocrinology (1998)
- Svensson J et al. — “Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure” — Journal of Clinical Endocrinology & Metabolism (1998)
- Ankersen M et al. — “Discovery of the first selective GH secretagogue, ipamorelin” — Journal of Medicinal Chemistry (1998)
- PubMed Search — Ipamorelin Growth Hormone Research Literature
- PubMed Search — GHS-R1a Ghrelin Receptor Agonist Studies
